NSC23925 is primarily investigated for its potential in cancer research, particularly in overcoming drug resistance in chemotherapy. It has shown promise in sensitizing cancer cells to conventional treatments, making it a valuable candidate for combination therapies. Research suggests it may inhibit specific pathways that contribute to multidrug resistance, thereby enhancing the efficacy of chemotherapeutic agents. Additionally, it is being explored for its role in targeting aggressive cancers, such as ovarian and breast cancer, where resistance to treatment is a significant challenge. Its application in preclinical studies highlights its potential as a therapeutic agent in oncology.